Mineralocorticoid Receptor Antagonists in End Stage Renal Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 118 participants.
Also called NCT01691053
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 118 participants
- Registry
-
NCT01691053 -
2011-003179-12
-
- Other papers using this trial's data
- The effect of spironolactone on diastolic function in haemodialysis patients
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany
- Registry status
- Completed
Technical summary
Registry record NCT01691053. Randomized; quadruple masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2017-02-14 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Mineralocorticoid Receptor Antagonists in End Stage Renal Disease
- Acronym
- MiREnDa
- Condition
- End Stage Renal Disease / Hemodialysis
- Intervention (Drug)
- Spironolactone
- Intervention (Drug)
- Placebo
- Lead sponsor
- Wuerzburg University Hospital
- Collaborator
- German Federal Ministry of Education and Research
- Collaborator
- Clinical Trial Center Wuerzburg (CTCW)
Record details
- Record id
cardio:ct-nct01691053- Content hash
bafc89604a21d098288fed570325c3e1933ad70dcc3bd199bd95754bbfcca97f